ArticleMarine drugs2019
Identification of Cyanobacterial Strains with Potential for the Treatment of Obesity-Related Co-Morbidities by Bioactivity, Toxicity Evaluation and Metabolite Profiling.
Article in Marine drugs, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Unveiling the Biotechnological Potential of Cyanobacteria from the Portuguese LEGE-CC Collection Through Lipidomics and Antioxidant and Lipid-Lowering Properties.Molecules (Basel, Switzerland) · 2025Article
- Phenotypic screening in zebrafish larvae identifies promising cyanobacterial strains and pheophorbide a as insulin mimetics.Scientific reports · 2024Article
- Recent Advances of the Zebrafish Model in the Discovery of Marine Bioactive Molecules.Marine drugs · 2024Review
- Screening of Lipid-Reducing Activity and Cytotoxicity of the Exometabolome from Cyanobacteria.Marine drugs · 2024Article
- Metabolite Profile Characterization of Cyanobacterial Strains with Bioactivity on Lipid Metabolism Using In Vivo and In Vitro Approaches.Marine drugs · 2023Article
- Article
- A Multiplex Molecular Cell-Based Sensor to Detect Ligands of PPARs: An Optimized Tool for Drug Discovery in Cyanobacteria.Sensors (Basel, Switzerland) · 2023Article
- Naturally Occurring Functional Ingredient from Filamentous Thermophilic CyanobacteriumAntioxidants (Basel, Switzerland) · 2022Article
- What Zebrafish and Nanotechnology Can Offer for Cancer Treatments in the Age of Personalized Medicine.Cancers · 2022Review
- Cytotoxicity andHeliyon · 2022Article
- Potential Anti-Obesity, Anti-Steatosis, and Anti-Inflammatory Properties of Extracts from the MicroalgaeMarine drugs · 2021Article
- A cross-sectional study on gut microbiota in prostate cancer patients with prostatectomy or androgen deprivation therapy.Prostate cancer and prostatic diseases · 2021Article
- Inhibition of Intestinal Lipid Absorption by Cyanobacterial Strains in Zebrafish Larvae.Marine drugs · 2021Article
- Berberine modulates deacetylation of PPARγ to promote adipose tissue remodeling and thermogenesis via AMPK/SIRT1 pathway.International journal of biological sciences · 2021Article
- Whole brain radiotherapy induces cognitive dysfunction in mice: key role of gut microbiota.Psychopharmacology · 2020Article
- The Marine SeagrassMarine drugs · 2020Article
- Double the Chemistry, Double the Fun: Structural Diversity and Biological Activity of Marine-Derived Diketopiperazine Dimers.Marine drugs · 2019Review
- New Aromatic Bisabolane Derivatives with Lipid-Reducing Activity from the Marine SpongeMarine drugs · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Obesity is a complex disease resulting in several metabolic co-morbidities and is increasing at epidemic rates. The marine environment is an interesting resource of novel compounds and in particular cyanobacteria are well known for their capacity to produce novel secondary metabolites. In this work, we explored the potential of cyanobacteria for the production of compounds with relevant activities towards metabolic diseases using a blend of target-based, phenotypic and zebrafish assays as whole small animal models. A total of 46 cyanobacterial strains were grown and biomass fractionated, yielding in total 263 fractions. Bioactivities related to metabolic function were tested in different
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.